FDA's Arthritis Drugs Advisory Committee recommends Celebrex approval

The FDA's Arthritis Drugs Advisory Committee has voted to recommend approval of Pfizer's Celebrex for use in juvenile rheumatoid arthritis, despite long-term safety concerns. They recommended that, if approved, Pfizer continues to study long-term safety and establish a patient registry.

You must be a registered member of MMM to post a comment.
close

Next Article in Legal/Regulatory